SOMERSET, N.J., Jan. 16, 2012 -- /PRNewswire/ -- Terumo Americas Holding, Inc. (TAH), a U.S. subsidiary of Japan's Terumo Corporation, one of the world's leading medical device manufacturers with $4 billion in sales and operations in more than 160 nations, today announced that it has acquired Onset Medical Corporation ("Onset"), an innovative medical device company located in Irvine, CA, that focuses on developing first-in-class access sheath technology designed for multiple, minimally invasive clinical applications in cardiology and urology.
Using its proprietary Controlled Deployment Technology (CDT) platform, Onset has developed the smallest sheath profiles with the largest internal diameters of any available access sheath to protect against unnecessary access site or arterial trauma for the patient. Onset's Associates will join with TAH subsidiary Terumo Medical Corporation as part of its Terumo Interventional Systems (TIS) business unit, where the CDT platform will complement TIS' complete product line of industry leading entry site management and lesion access technologies.
Terumo customers will have access to Onset's complete product lines. The SoloPath™ Balloon Expandable Transfemoral and Transseptal Catheters' expandable and collapsable sheath technology allows TIS to enter the global structural heart and aneurysmal repair markets, providing an access platform for complex, large-bore procedures including Transcatheter Aortic Valve Implantation (TAVI), Thoracic Endovascular Aortic/Aneurysm Repair (TVAR) and Endovascular Aneurysm/Aortic Repair (EVAR). The Pathway™ Balloon Expandable PCNL Sheath and Pathway™ Balloon Expandable Ureteral Access Sheath provide physicians with a one-step option for performing procedures such as Percutaneous Nephrolithotomy in the removal of large renal calculi (kidney stones).
"We welcome Onset to the Terumo family and look forward to providing our customers with current and future products based on the exciting CDT platform, which represents a tremendous complement to our overall value proposition as the leaders in entry site management and lesion access," said James Rushworth, Senior Vice President and General Manager, Terumo Medical Corporation and President, Onset Medical Corporation. "CDT literally changes the way physicians enter the vascular system and manage the access site, while allowing them to achieve easier, safer access to the target lesion in a variety of clinical applications. This strategic acquisition reinforces our commitment to pursuing unique technologies that meet the specialized needs of our customers and contribute to better outcomes for their patients."
As a global leader in vascular access management, TIS can effectively maximize the potential of the CDT-based platform when compared with competitors who do not specialize in entry site management.
"When Terumo approached us, it quickly became clear that they were the established leader in entry site management and the best company to commercialize our sheath technology on a global scale," said Joseph Bishop, Vice President and Chief Operating Officer, Onset Medical Corporation. "It is gratifying to know that our unique devices will immediately strengthen their core capability and will be featured prominently among other class-leading technologies that drive better patient outcomes."
For more information, contact Robert Murphy, The Storch-Murphy Group, 908.276.0777.
Terumo Interventional Systems
Terumo Interventional Systems (TIS), a strategic business unit of Terumo Medical Corporation, directly markets a full line of guidewires, catheters, introducer sheaths, guiding sheaths and embolization products for use in a multitude of different interventional procedures. Interventional Radiologists, Interventional Neuroradiologists, Interventional Cardiologists, and Vascular Surgeons are among the medical professionals that depend upon TIS products to access and cross difficult-to-reach lesions, thereby allowing therapeutic intervention in previously unreachable vascular beds.
Terumo Medical Corporation
Founded in 1972 as a Terumo Corporation subsidiary, Terumo Medical Corporation (TMC) develops, manufactures, and markets high-quality medical devices used in a broad range of applications in numerous healthcare markets. TMC manufactures a broad portfolio of needles and syringes, entry-site management products, and a line of sterile connection devices used in hospitals and blood banks worldwide.
Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers with $4.0 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures, and distributes world-class medical devices including products for use in cardiothoracic surgery, interventional procedures, and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician office use. Terumo contributes to society by providing valued products and services to the healthcare market and by responding to the needs of healthcare providers and the people they serve. Terumo Corporation's shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543: JP) and is a component of the Nikkei 225, Japan's leading stock index.
SOURCE Terumo Americas Holding, Inc.